MYL News and Press, Mylan N.V. From 03/15/20

Choosing between biotech giants Biogen (NASDAQ: BIIB) and Amgen (NASDAQ: AMGN) is not an easy task. Both companies have attractive pipelines and solid suites of products on the market. Though Amgen's revenue declined in 2019 while Biogen's rose, Amgen offered a better revenue outloo...

Drug stocks soared on Friday with the overall stock market rebounding from Thursday's historic sell-off. Several also spiked near the end of the day today as President Trump held a news conference where he declared a national emergency that he said would "open up access" to up to $50 billion to ...

Pharma giants Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) share similar visions for the future. Both aim to transform into smaller, nimbler biopharmaceutical outfits focused on high-value R&D. Last year, investors witnessed the strategy begin to take shape at both businesses. ...

HERTFORDSHIRE, England and PITTSBURGH , March 10, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. District Court of New Jersey found the device patent claims (U.S. Patent No. 9,526,844) asserted by Sanofi against Mylan's insulin glargine product not ...

Mylan Pharmaceuticals ULC Launches Wixela® Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the First Available Bioequivalent Alternative to ADVAIR® DISKUS® (fluticasone propionate and salmeterol inhalation powder) in Canada Canada NewsWire...

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , March 9, 2020 /PRNewswire/ -- Mylan N.V .  (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License A...

2019 Earnings Pfizer ( PFE ) has fallen considerably over the last few months due to uncertainty of business and most recently a miss on Q4 earnings that has been a driving factor in the company's nearly 20% decline in share price since January 28 when they were released. (Source: Stock...

Image source: The Motley Fool. Mylan N.V.   (NASDAQ: MYL) Q4 2019 Earnings Call Feb 27, 2020 , 4:30 p.m. ET Operator Continue reading

Mylan N.V. (MYL) Q4 2019 Earnings Conference Call February 27, 2020 4:30 AM ET Company Participants Melissa Trombetta – Head-Global Investor Relations Heather Bresch – Chief Executive Officer Rajiv Malik – President Ken Parks – Chief Financial Office...

Mylan (NASDAQ: MYL) was down by almost 4% in after-market trading on Thursday, following the release of its Q4 of fiscal 2019 results in late afternoon.  The pharmaceutical giant managed to raise its total revenue by 4% on a year-over-year basis during the quarter, to $3.19 billion. ...